(Inclusive of all taxes)
Zufinib 250 mg Tablet is an anti-cancer drug used for treating non-small cell lung cancer (NSCLC) that has spread to other parts of the body, in patients with abnormal EGFR genes who haven't received prior cancer treatment. This Zufinib 250 Tablet is not suitable for children or adolescents as its safety and effectiveness in these groups are unknown.
Zufinib 250 Tablet may cause side effects, including diarrhoea, skin rash, and nausea. It may also cause serious side effects, such as liver damage and lung inflammation. It is important to talk to your doctor about any side effects you experience while taking Zufinib 250 mg.
Do not use if you have an allergy to Zufinib Tablet or any of its ingredients. Before using this Zufinib 250 Tablet, consult your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Before taking Zufinib 250 Tablet talk to your doctor about the potential risks and benefits of taking this medication, as well as any other questions or concerns you may have and also important to let your doctor you have any pre-existing diseases or using any medications, vitamins supplements, herbal medicine you are taking.
Non-small cell lung cancer: Zufinib 250 mg Tablet is used to treat non-small cell lung cancer, which is a type of lung cancer that affects a large number of cells in the lung.
Zufinib 250 Tablet inhibits a protein called epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. By inhibiting this protein, Zufinib can help to slow the progression of cancer.
Zufinib Tablet may be able to help reduce the severity of cancer-related symptoms, such as pain and fatigue, which may improve the patient's overall quality of life.
Zufinib 250 mg Tablet may be used in combination with other cancer treatments, such as chemotherapy, to improve their effectiveness.
Like all medications, Zufinib 250 mg Tablet can cause side effects but do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them.
Zufinib Tablet may take with or without food. Swallow the tablet whole with a full glass of water. Do not crush, chew, or open the tablet. If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.
Zufinib Tablet works by inhibiting the activity of the epidermal growth factor receptor (EGFR) protein, which is found on the surface of cells and is involved in the growth and proliferation of cancer cells. When EGFR is activated, it sends signals to the inside of the cell to grow and divide. Zufinib 250 mg binds to the EGFR and prevents it from activating, thereby inhibiting the growth and proliferation of cancer cells.
Zufinib Tablet may cause dizziness, fatigue, and difficulty concentrating and coordinating, which may affect your ability to drive a vehicle safely. It is important to follow your doctor's instructions and take necessary precautions such as avoiding driving a vehicle or operating heavy machinery if you suffer from the side effects of this Zufinib 250 mg.
It is not recommended to breastfeed while taking Zufinib 250 mg. Zufinib Tablet may pass into breast milk and harm the infant. If you are breastfeeding and taking Zufinib, it is important to talk to your doctor about the possible risks and benefits of continuing to breastfeed. Your doctor will be able to help you make the best decision for you and your baby's health.
Zufinib Tablet is safe for use in patients with mild to moderate liver disease, no dose adjustment of Zufinib 250 mg Tablet is recommended. The use of Zufinib is not recommended for severe liver disease patients. It is important to discuss all of your medical conditions and medications with your doctor to ensure that the treatment plan is safe and effective for you.
Use of Zufinib Tablet may be unsafe during pregnancy as animal studies indicate that it may harm the developing foetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Zufinib 250 Tablet during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.
Zufinib 250 Tablet is safe for use in patients with mild to moderate kidney disease, no dose adjustment of Zufinib 250 mg Tablet is recommended. The use of Zufinib 250 mg Tablet Tablet is not recommended for severe kidney disease patients. It is important to discuss all of your medical conditions and medications with your doctor to ensure that the treatment plan is safe and effective for you.
It is generally not recommended to drink alcohol while taking Zufinib 250 mg. It may increase the risk of liver damage. it is best to avoid alcohol or limit your alcohol consumption while taking any medication.
1. Gefitinib Tablets, Natco Pharma (Canada) Inc. Mississauga, Product Leaflet
2. Iressa 250 Mg Film-coated Tablets, AstraZeneca Ab, Product Monograph
3. Summary Of Risk Management Plan For Gefitinib 250 Mg Film-coated Tablets, Qilu Pharma Spain S.l. Available Form
4. Iressa (gefitinib Tablets, AstraZeneca Pharmaceuticals Lp, Uk, Product Monograph
5. Iressa 250 Mg Film Coated Tablets, AstraZeneca Limited, Product Leaflet
6. Gefitinib 250 Mg Film-coated Tablet, Available Form